KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Inovio Pharmaceuticals (INO) over the last 17 years, with Q3 2025 value amounting to $36.6 million.

  • Inovio Pharmaceuticals' Cash & Equivalents rose 6861.07% to $36.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $36.6 million, marking a year-over-year increase of 6861.07%. This contributed to the annual value of $65.8 million for FY2024, which is 35988.35% up from last year.
  • According to the latest figures from Q3 2025, Inovio Pharmaceuticals' Cash & Equivalents is $36.6 million, which was up 6861.07% from $24.4 million recorded in Q2 2025.
  • Over the past 5 years, Inovio Pharmaceuticals' Cash & Equivalents peaked at $83.6 million during Q1 2021, and registered a low of $14.3 million during Q4 2023.
  • In the last 5 years, Inovio Pharmaceuticals' Cash & Equivalents had a median value of $39.9 million in 2025 and averaged $42.4 million.
  • Per our database at Business Quant, Inovio Pharmaceuticals' Cash & Equivalents plummeted by 7264.79% in 2021 and then soared by 35988.35% in 2024.
  • Quarter analysis of 5 years shows Inovio Pharmaceuticals' Cash & Equivalents stood at $71.1 million in 2021, then plummeted by 34.88% to $46.3 million in 2022, then plummeted by 69.11% to $14.3 million in 2023, then surged by 359.88% to $65.8 million in 2024, then tumbled by 44.44% to $36.6 million in 2025.
  • Its last three reported values are $36.6 million in Q3 2025, $24.4 million for Q2 2025, and $39.9 million during Q1 2025.